entertainment -WSS

entertainment

author：entertainment 2025-09-29 20:17:18 - browse：81

The ability of cancer cells to move and spread depends on actin-rich core structures such as the podosomes (yellow) shown here in melanoma cells. Cell nuclei (blue), actin (red), and an actin regulator (green) are also shown. — Metastatic melanoma cells Julio C. Valencia,/NCI Center for Cancer Research

Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from Iovance, is the first cell therapy approved for a solid tumor.

“It’s so exciting and gratifying,” said Allison Betof Warner, a cell therapy researcher and physician at Stanford University who has worked on Amtagvi. “This is a game-changing moment for our field. We’ve seen huge success of cellular therapy for hematologic malignancies, and we’ve yet to capitalize on that for solid tumors. This is hopefully the first of many to come.”

In a Phase 2 clinical trial, titled C-144-01, 153 patients who had already been on a median of three prior lines of therapy received lifileucel, and 31% of them responded to therapy. “These are in very late line patients. They’ve exhausted every standard care option,” Betof Warner said. “The most promising part of this therapy for me is that 42% of patients who responded were still responding for 18 months or longer. It’s truly incredible.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： As a primary care physician, here's how I hope to partner with AI

focus

WSS

UnitedHealth argues against case alleging wrongful AI care denials

Why medical students are struggling with mental health

At flashy new research hub, AstraZeneca lays out ambitious growth goals

Addressing health care workers' trauma can help fight burnout

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

In key trial, Verve's treatment lowers cholesterol levels in patients

knowledge

entertainment

explore

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Wildfire smoke exposes gaps in outdoor worker protections

FDA's Woodcock to retire early next year

Supreme Court strikes down use of affirmative action

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Walensky prepares to leave CDC — and Congress — behind

Poor hospice wound care hurts patients and families

focus

UnitedHealth argues against case alleging wrongful AI care denials

Astellas still sees hope in its gene therapy after four deaths

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Cue Health, Covid

Wegovy, Zepbound and weight loss drugs that preserve muscle

Why medical students are struggling with mental health

explore

focus

entertainment

hotspot